Prevention and post-exposure management of occupational exposure to Ebola virus

Michael A. Moso*, Chuan K. Lim, Eloise Williams, Caroline Marshall, James McCarthy, Deborah A. Williamson

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

5 Citations (Scopus)

Abstract

There have been significant advances in the prevention and management of Ebola virus disease (EVD) caused by Zaire Ebola virus (ZEBOV), including the development of two effective vaccines, rVSV-ZEBOV and Ad26.ZEBOV/MVA-BN-Filo. In addition, ZEBOV monoclonal antibodies have become first-line therapy for EVD. However, the 2022–23 outbreak of Sudan Ebola virus (SUDV) in Uganda has highlighted the gap in current therapies and vaccines, whose efficacy is uncertain against non-ZEBOV species. Health-care and laboratory staff working in EVD treatment centres or Ebola virus diagnostic and research laboratories face unique risks relating to potential occupational exposure to Ebola viruses. Given the substantial morbidity and mortality associated with EVD, facilities should have strategies in place to manage occupational exposures, including consideration of post-exposure therapies. In this Review, we discuss currently available evidence for prevention and post-exposure prophylaxis of EVD, including therapies currently under evaluation for SUDV.

Original languageEnglish
Pages (from-to)e93-e105
JournalThe Lancet Infectious Diseases
Volume24
Issue number2
DOIs
Publication statusPublished - Feb 2024
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2024 Elsevier Ltd

Fingerprint

Dive into the research topics of 'Prevention and post-exposure management of occupational exposure to Ebola virus'. Together they form a unique fingerprint.

Cite this